PF-07224826 / Pfizer - LARVOL DELTA

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Pfizer | N=110 ➔ 0 | Not yet recruiting ➔ Withdrawn

Combination therapy • Enrollment change • Metastases • Trial withdrawal • Breast Cancer • Endometrial Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Liposarcoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • Triple Negative Breast Cancer • HER-2

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=110 | Not yet recruiting | Sponsor: Pfizer | Trial completion date: Oct 2027 ➔ Apr 2028 | Initiation date: Jul 2023 ➔ Jan 2024 | Trial primary completion date: Oct 2025 ➔ Apr 2026

Combination therapy • Metastases • Trial completion date • Trial initiation date • Trial primary completion date • Breast Cancer • Endometrial Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Liposarcoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • Triple Negative Breast Cancer • HER-2

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=110 | Not yet recruiting | Sponsor: Pfizer

Combination therapy • Metastases • New P1 trial • Breast Cancer • Endometrial Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Liposarcoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • Triple Negative Breast Cancer • HER-2